RESEARCH PAPER

Mesoporous Silica Nanoparticles for Drug Encapsulation

Kuldeep Bansal [1], Kapil Mundada [2], Vratika Arya [3], Dr. Narendrakumar J. Suryavanshi [4], Dr. Amar Mohite [5], Ms. Aishwarya D. Jagtap[6]

[1]*Assistant Professor Department of Pharmaceutical Chemistry Arya College of Pharmacy Jaipur, Rajasthan, India*
Email: kuldeep.bansal@aryajaipur.com
[2].*Associate Professor Department of Instrumentation and Control Engineering Vishwakarma Institute of Technology Pune, Maharashtra – 411037, India*
Email: kapil.mundada@vit.edu
[3].*Assistant Professor School of Allied Health Sciences Noida International University Uttar Pradesh – 203201, India*
Email: vratika.arya@niu.edu.in
[4].*Assistant Professor Krishna Institute of Science and Technology Krishna Vishwa Vidyapeeth (Deemed to be University) Taluka-Karad, Dist-Satara – 415539 Maharashtra, India*
Email: njsuryawanshi1981@gmail.com
[5].*Assistant Professor Krishna Institute of Science and Technology Krishna Vishwa Vidyapeeth (Deemed to be University) Taluka-Karad, Dist-Satara – 415539 Maharashtra, India*
Email: armohitept@gmail.com
[6].*Assistant Professor Krishna Institute of Science and Technology Krishna Vishwa Vidyapeeth (Deemed to be University) Taluka-Karad, Dist-Satara – 415539 Maharashtra, India*
Email: aishwarya22999@gmail.com

ABSTRACT
Because of its unique structural qualities a high surface area, pore diameters that may be altered, and biocompatibility mesoporous silica nanoparticles (MSNs) are attracting a lot of interest in the field of drug delivery. These features make MSNs ideal for enclosing medicinal substances and releasing them gradually. MSNs may be created to carry many different medications, including ones that either dislike water or ones that do. Their porous structure enables several medicinal molecules fit within. Surfaces of MSNs can also be altered to target certain cells or tissues, increase their stability, and assist in drug carrying capacity. MSNs have therefore been developed as effective means of delivering a variety of therapeutic drugs, including cancer therapies, gene therapy, and antibiotics. MSNs are among the finest as they allow encapsulated pharmaceuticals to remain unbroken. This maintains the medicinal agent's stability till it reaches its intended spot. Drug release from MSNs can frequently be triggered by external cues such variations in pH, temperature, or light. This allows one to control the release rate of medications. Targeting moieties to the surface of medications, such as peptides or antibodies, helps them to be delivered specifically to certain cells, therefore improving the therapeutic efficiency and lowering adverse effects. Though MSN-based medication delivery systems provide several advantages, their practical deployment is currently challenging. Among these issues include development, long-term safety, and maybe injury. Still, researchers are working hard to discover solutions to these challenges; MSNs are still viewed as a valuable and robust resource for developing improved drug delivery systems that may be applied in a range of therapeutic environments
Keywords: Mesoporous silica nanoparticles, drug delivery, controlled release, surface functionalization, targeted therapy
How to cite this article: Bansal K, Mundada K, Arya V, Suryavanshi NJ, Mohite A, Jagtap AD, Mesoporous Silica Nanoparticles for Drug Encapsulation.Int J Drug Deliv Technol. 2026;16(1s): 92-100; DOI: 10.25258/ijddt.16. 92-100
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Drug delivery has evolved significantly within the last several decades. The objective is to lower adverse effects and increase the efficacy of medications in curing diseases. Conventional drug delivery techniques can suffer in not being bioavailable, not being stable, and not being able to target the correct sites. These issues make their treatment of some illnesses less successful. These issues are driving increasing interest in drug delivery techniques based on nanotechnology, particularly those using nanoparticles to convey medications. Mesoporous silica nanoparticles (MSNs) have emerged as a viable alternative among all the several types of nanoparticles due to their special structure and versatility in several applications. MSNs are silica-made inorganic nanoparticles. Their well-ordered, mesoporous structure with plenty of surface area, many pores, and changeable size reflects their nature. These qualities make MSNs ideal for covering a broad spectrum of medications, including those with hydrophobic or hydrophilic components.

MSNs' vast surface area, which results from their mesoporous shape, allows them to retain plenty of medications. The dimensions and form of the pores allow one to satisfy the requirements of several therapeutic uses. Controlling a lot of medications increases the efficiency of drug transportation, so therapeutic effects linger for longer. Apart from their great surface area and porosity, MSNs are also very biocompatible, which qualifies them for usage in

*Author for Correspondence: Kuldeep Bansal

biological environments. They are siliceous, so they are not extremely damaging when introduced into live entities; moreover, they are easy to modify to provide them additional stability, targetability, and value. Functional groups can be included on the surface of MSNs to target certain cells or tissues, set off specific drug release triggers, and increase drug loading efficiency. This surface modification enables the development of smart drug delivery systems capable of reacting to environmental stimuli such pH, temperature, or certain biomarkers, therefore releasing medications in a targeted and regulated manner. MSNs are among the greatest things because they may contain a wide range of therapeutic agents, including proteins, peptides, nucleic acids, medicines that poorly dissolve in water, and other physiologically active compounds. Many of these compounds have issues being soluble, stable, and releasing medications in a regulated manner when introduced into standard drug delivery systems [1]. These compounds can be released exactly when needed and their stability is enhanced by being housed inside the mesoporous structure of MSNs. MSNs are therefore excellent for delivering chemotherapeutic medications as regulated release is required to ensure the treatments work and generate as little adverse effects as feasible.

Furthermore allowing MSNs to serve several purposes are their great surface area and porous nature. Targeting ligands—like antibodies, peptides, or small molecules—can be added to MSNs to modify them [2]. This allows medications be administered just to certain tissues or cells. By means of this focused medication administration, the treatment performs better and is less detrimental to healthy tissues. Targeting certain receptors or biomarkers overexpressed on the surface of cancer cells helps chemotherapy medications be delivered straight to the tumour location. This increases the efficacy of the treatment and lowers negative effects across the entire body. MSNs offer great potential as drug delivery systems, but significant issues still need to be resolved before they may be applied in clinical environments. The mesoporous silica nanoparticles in Figure 1 make controlled drug release easier because of their porous shape.



Figure 1: Illustrating Mesoporous Silica Nanoparticles for Drug Encapsulation

For MSN-based drug delivery systems to fully reach their clinical potential, problems like large-scale production, long-term stability, and possible toxicity must be solved. These problems are still being worked on, but nanomedicine research and technological progress are working hard to find solutions. MSNs are still an exciting way to create advanced, effective, and targeted drug delivery systems.

RELATED WORK

Because of its adaptability and original structure, mesoporous silica nanoparticles (MSNs) have attracted a lot of interest in drug delivery research. Numerous studies have indicated that MSNs might be valuable medication transporters for a variety of medicinal uses. These results reveal that MSNs may effectively encapsulate hydrophobic as well as hydrophilic medicines. Among the first studies examining MSNs as a potential medication delivery method was Vallet-Regí et al. (2001 [3]. Their great surface area and changeable pore size turned out to be two crucial elements influencing the effectiveness of drug encapsulation. According to the study, MSNs may safely retain and release medications including cancer-fighting treatments as well as medicines. This makes them a suitable fit for accepted medication delivery strategies. Since then, several research have investigated how MSNs may be employed to convey various kinds of medicinal substances, including proteins, peptides, and nucleic acids, which are difficultly obtained in the conventional manner [4]. Surface modifications developed to improve MSN-based drug delivery systems in terms of drug carrying capacity and drug release control marked a significant advancement in these systems. Bhardwaj et al. investigated including amino, thiol, and carboxyl groups on MSN surfaces in 2011. These modifications, they discovered, enhanced the speed of release and made the medications within more stable. By binding certain ligands such as antibodies, peptides, or tiny molecules, surface functionalisation can also assist precisely distribute medications. Functionalised MSNs, according to Shi et al., might target cancer cells especially via attaching to overexpressed receptors on the cell surface. A lot of studies recently have focused on developing "smart" MSNs that can react to variables like pH, temperature, or light as this helps the medicine concentrate more at the tumour site and lowers its systemic toxicity [5]. Li et al. created MSNs with pH-sensitive coatings allowing medications to be delivered gradually in acidic environments—that is, tumours. This method has the benefit of targeted drug delivery, which means that the drug is only released in the right place, so it has less of an effect on healthy tissues [6]. Bustos et al. built on this idea by creating light-responsive MSNs that release their drug payload when they come into contact with near-infrared light. Table 1 summarizes related work, highlighting applications, future trends, benefits, and their impact. This gives researchers even more control over when and where drugs are delivered

Table 1: Summary of Related Work

Application	Future Trend	Benefits	Impact
Cancer Therapy	Targeted drug delivery using personalized ligands	Improved specificity and reduced systemic toxicity	Enhances therapeutic efficacy while reducing side effects
Antibiotic Delivery	Incorporation of smart responsive systems for release	Sustained release, overcoming bacterial resistance	Helps in the fight against drug-resistant infections
Gene Therapy	Gene silencing through RNA delivery	Efficient gene transfer with minimal toxicity	Paves the way for safer and more effective gene therapies
Neurological Disorder Treatment	Enhanced BBB penetration using modified MSNs	Improved drug delivery to brain with reduced side effects	Enables treatment of neurological diseases with fewer side effects
Chronic Disease Management [7]	Long-term release for chronic conditions	Increased patient compliance with sustained release	Ensures more consistent treatment and less frequent administration
Immunotherapy	Synergistic use with immunomodulatory drugs	Improved immune response and tumor targeting	Increases the effectiveness of cancer immunotherapy
Protein Delivery	Development of delivery systems for therapeutic proteins	Enhanced stability and bioavailability of proteins	Solves challenges in protein delivery and stability
Vaccination [8]	Nanoparticle-based platforms for enhanced vaccine delivery	Increased efficiency and protection of vaccines	Improves vaccination strategies, especially in infectious diseases
Combination Therapies	Multifunctional MSNs for combination therapy	Better therapeutic outcomes through combination therapies	Provides more effective treatments for complex diseases
Personalized Medicine	Integration of MSNs with patient-specific therapy	Customized treatments leading to personalized healthcare	Enables better patient-specific treatments, improving outcomes
In vivo Imaging	Use of MSNs as carriers for imaging agents	Non-invasive, real-time tracking and monitoring	Enhances the ability to track treatment progress and disease progression

MATERIALS AND METHODS

A. Materials Used

1. Silica sources

When making mesoporous silica nanoparticles (MSNs), silica sources are very important because they decide the final nanoparticle's chemical and physical properties. Sodium silicate, tetraethyl orthosilicate (TEOS), and tetramethyl orthosilicate (TMOS) are the silica precursors that are used most often. TEOS is the most common precursor used because it is easy to get, doesn't take long to work, and can combine with surfactants to make well-ordered mesoporous structures [9]. When water is added to TEOS, it goes through hydrolysis and condensation reactions. This creates a silica network that eventually turns into mesoporous silica nanoparticles. The surface area, pore size distribution, and overall shape of the MSNs are all affected by the silica precursor that is used. In this case, using TMOS might lead to particles that are smaller than using TEOS [10].

Also, silica nanoparticles made from sodium silicate are often used on a large scale because they are cost-effective, though it may take extra steps to control the particle size and make the pore structure uniform. Organosilicon compounds like silane-based functional groups (for example, aminopropyltriethoxysilane or APTES) are other sources of silica. These compounds can add certain functional groups to the MSN surface. These functional groups can be used to change the way MSNs' surfaces behave, make drug loading better, or make targeted drug delivery easier [11]. The silica source chosen is very important for determining the final properties of MSNs, such as their ability to encapsulate drugs, their stability, and their suitability for certain biomedical uses.

2. Drugs selected for encapsulation

The choice of medications that can be included in mesoporous silica nanoparticles (MSNs) depends on several factors including how easily the drug dissolves, how stable it is, and how therapeutally useful it is. From antibiotics and biologics that do to chemotherapeutic medications that dislike water, MSNs may effectively hold

*Author for Correspondence: Kuldeep Bansal

a lot of various kinds of pharmaceuticals. They are therefore quite helpful for conveying a variety of therapeutic substances. Often placed within MSNs are chemotherapeutic medications such doxorubicin (DOX), paclitaxel, and cisplatin as they do not dissolve well in water and have negative effects when administered otherwise [12]. By building a safe environment inside the nanopores and enabling regulated release, MSNs enable these medications breakdown and be absorbed by the body better. One often used chemotherapeutic agent, DOX, for instance, has been effectively contained in MSNs to improve its loading capacity and target cancer cells simultaneously. Apart from cancer treatments, MSNs have also been sent medications, usually meant to combat diseases brought on by germs. Often encased in MSNs are hydrophilic antibiotics such gentamicin, tetracycline, and ciprofloxacin.

These ensure that the medications be delivered gradually over time and prevent their too rapid breakdown. Healing long-term diseases or reducing germ resistance—a growing concern in modern medicine— depends on controlled release, so it is rather crucial. Furthermore under consideration as a means of delivering biologics including nucleic acids, proteins, and peptides are MSNs [13]. Many often, these drugs have side effects like instability, poor penetration, and breakdown by body enzymes. By placing biologics within MSNs, which guarantees their safety and speeds them to the target location, these issues can be resolved. MSNs are very useful as drug carriers because they can hold a lot of different drugs with different physical and chemical qualities. Because MSNs are so flexible and can control how drugs are released, they are a great starting point for making the next generation of drug delivery systems.

B. Synthesis of Mesoporous Silica Nanoparticles

1. Preparation of silica solution

An important part of making mesoporous silica nanoparticles (MSNs) is making a silica solution. This is because the quality and properties of the final nanoparticle product depend on it. Most of the time, a silica precursor is dissolved in a good liquid to make a silica solution. This starts hydrolysis and condensation processes that finally form silica networks. Most of the time, tetraethyl orthosilicate (TEOS) is used as a silica precursor because it is very reactive and can create mesoporous structures [14]. TEOS is mixed with an alcohol, usually ethanol, to make the silica solution. The alcohol dissolves the TEOS. After that, water is added to help the hydrolysis process along. To control the rate of the reaction, an acid or base agent is added, like hydrochloric acid or ammonium hydroxide. The solution's pH is very important because it affects how the silica molecules condense and the size of the nanoparticles that are made. When TEOS is exposed to acid, it breaks down into smaller pieces called silica nanoparticles. This happens because the ethoxy groups in TEOS are changed by hydroxyl groups. The temperature and stirring speed can be changed, along with the amounts of the precursor and liquid used, to change the MSNs' size, shape, and surface qualities. Surfactants or template-making substances may also be added to the fluid in some versions of the process to help make ordered mesopores. Surfactants combine with the growing silica structure to help keep the development of nanopores stable [15]. Once the silica solution is ready, the gelation process starts. This makes nanoparticles with the right mesostructure, which includes the right hole size and surface area.

2. Sol-gel method or template-assisted method

It is common to use both the sol-gel method and the template-assisted method to make mesoporous silica nanoparticles (MSNs). Both methods depend on the precursor's ability to go through hydrolysis and condensation processes. However, the two methods are different in how they control the structure and shape of the nanoparticles. We often use the sol-gel method to make MSNs because it is easy and effective. Silica ingredients like tetraethyl orthosilicate (TEOS) or tetra-n-propyl orthosilicate (TPOS) are mixed with builders and helpers to create a sol in this method. The sol gellates, which means the particles get bigger and stick together, making a gel. We then dry and sometimes heat the gel to get rid of the surfactant template and get mesoporous silica nanoparticles.

The sol-gel method is very adaptable because it lets you finetune things like temperature, pH, and the make-up of the liquid. These changes can have an effect on the end mesopore size, surface area, and particle shape. This method works especially well when you want to make particles with lots of surfaces and even hole patterns. The template-assisted method, on the other hand, guides the formation of mesopores with a hard or soft template. The hard templates, which are usually made of styrofoam or silica spheres, act as a framework for the silica preparation to stick to. Once the silica has been deposited, the template is usually taken away by etching or heating, leaving behind well-ordered mesopores. Surfactants, which form micelles in solution, are often used in the soft template method. The surfactant molecules arrange themselves into circular or cylindrical shapes on their own, and the silica precursor is then put on top of these micelles. \

Step 1. Hydrolysis of Silica Precursor (TEOS)

The first step in the sol-gel method is the hydrolysis of tetraethyl orthosilicate (TEOS), a common silica precursor. Water is added to TEOS to break the ethoxy groups, forming silanol groups.

$Si(OC2H5)4 + H2O \rightarrow Si(OH)4 + 4\ C2H5OH$

Where:

- TEOS ($Si(OC2H5)4$) reacts with water ($H2O$),
- Producing silanol ($Si(OH)4$) and ethanol ($C2H5OH$).

Step 2. Condensation Reaction

After hydrolysis, the silanol groups undergo condensation reactions to form silica networks. This leads to the formation of a silica gel.

$Si(OH)4 + Si(OH)4 \rightarrow Si\text{-}O\text{-}Si + H2O$

Where:

- Two silanol groups react to form a silica-oxygen-silica bond (Si-O-Si), releasing water as a byproduct.

Step 3. Addition of Template (If Template-Assisted)

In template-assisted methods, surfactants or hard templates are introduced. Surfactants like cetyltrimethylammonium bromide (CTAB) form micelles that act as the template for mesopore formation.

$C16H33N(CH3)3Br \rightarrow C16H33N(CH3)3+ Br-$

Where:

- CTAB forms a micellar structure, and the surfactant molecules organize themselves into a template for the mesoporous structure.

Step 4. Silica Deposition Around the Template

The silica precursor ($Si(OH)4$) or TEOS deposits around the surfactant micelles or template, creating a mesoporous silica structure.

$Si(OH)4 + Template \rightarrow Silica\text{-}Template\ Complex$

Where:

- Silica begins to form around the template (e.g., surfactant micelles), encapsulating the template within the mesoporous structure.

Step 5. Removal of the Template

The final step involves the removal of the template, either through calcination or washing with a solvent. This step leaves behind the mesoporous structure.

$Silica\text{-}Template\ Complex \rightarrow Mesoporous\ Silica + Template\ Removal$

Where:

- The template is removed (typically by calcination or solvent extraction), leaving a mesoporous silica nanoparticle with controlled pore sizes.

IV. Properties of Mesoporous Silica Nanoparticles

A. Structure and morphology

MSNs are made up of mesoporous silicon particles that have a very ordered and regular mesostructure. This is a key part of how well they work as drug carriers. The main thing that determines the shape of MSNs is how they are made. Surfactants or patterns are used to help make well-defined, nanoporous materials. Mesoporous structures in MSNs are usually hexagonal, cubic, or worm-like, and their sizes range from 2 to 50 nm. These holes give drugs a lot of surface area to stick to, and they can be changed to fit different uses. The shape of MSNs changes depending on the variables used for production, such as the type of liquid, pH level, temperature, and amount of detergent present. Figure 2 shows the structure and shape of mesoporous silica nanoparticles, which shows off their special qualities.



Figure 2: Properties of Mesoporous Silica Nanoparticles - Structure and Morphology

By changing these things, it is possible to make MSNs with specific forms, such as spherical, rod-like, or cylindrical structures. Important determinants of the amount of drug the particles can store, the rate of drug release, and the speed with which cells may absorb them are their shape and size. The spherical type MSN is excellent for encapsulating a variety of medications as its pores are all of the same size and minimal surface change. Conversely, because of their irregular structure, which might make them more helpful for delivering medications in specific restorative circumstances, rod-shaped MSNs may be superior in interacting with cell membranes. One approach to considerably alter the surface characteristics and structure of MSNs is to add functional groups—such as amino, thiol, or carboxyl groups—to their surface. These adjustments facilitate loading, manage release, and provide the correct material count. MSNs are a handy building block for many different drug delivery systems as their overall structure and form are somewhat adaptable. This allows researchers great influence on their methods and capacity of action.

B. Surface area and porosity

Two key reasons the mesoporous silica nanoparticles (MSNs) are so effective in delivering medications are their surface area and porosity. Often greater than 1000 m^3/g, MSNs have a great specific surface area as they are mesoporous. Because it provides healing agents with numerous sites to interact, this huge surface area is crucial for efficiently encapsulating pharmaceuticals as it increases the drug loading capacity far above with conventional drug carriers. The porosity of MSNs allows medications to fit within them as it indicates empty spaces inside them. MSNs can contain many various kinds of medicinal compounds, including tiny chemicals, proteins, and nucleic acids as these holes can be precisely regulated and typically span 2 to 50 nm in size.

The MSNs' hole size and spread greatly affect how much drug they can hold, how they release the drug, and what kinds of drugs they can contain. For example, drugs with small molecules (less than 10 nm) can be put into MSNs with ease when the pores are small. But bigger organic molecules like proteins or nucleic acids need larger pores to be encapsulated properly. The regularity and order of the mesopores also help keep the drugs from leaking out too quickly. MSNs have linked pore networks that make sure drugs are released slowly over time. This keeps drugs from being released too quickly, which could cause unwanted side effects. You can make MSNs with better surface area and porosity by changing things like the type of silica precursor, the fluid, the temperature, and whether detergents or templates are present during the synthesis process.

C. Biocompatibility and biodegradability

Biocompatibility and biodegradability are important features for mesoporous silica nanoparticles (MSNs) if we want to use them for drug administration, especially in hospital settings. Because they are mostly made of silica,

which is harmless and not harmful to human cells, MSNs are usually thought to be very safe materials. Biocompatibility of MSNs is important to make sure that they have minimal negative effects on the body whether they are injected or put on the skin. Several studies have shown that MSNs can be used safely in living things without causing major immune reactions, inflammation, or cell death. Because they can work with living systems without hurting them, they can be used for a long time to treat diseases like cancer or control chronic conditions. Another important thing that makes MSNs more appealing for drug delivery methods is that they break down naturally. MSNs can slowly break down in the body, which is different from many manufactured nanoparticles. The breakdown of the silica network usually speeds up this process. This happens over time in settings with water and low pH. When things break down, harmless leftovers like silicon ions are released. These are naturally occurring in the body and are easily flushed out by the kidneys.

APPLICATIONS OF MSNS IN DRUG DELIVERY

A. Targeted drug delivery

Mesoporous silica nanoparticles (MSNs) have shown a lot of promise in the field of targeted drug delivery because they are very flexible and can easily be functionalised, which lets specific targeting ligands bind to them. These ligands can bind to receptors or proteins that are overexpressed on the surface of sick cells. This guides the drug-loaded nanoparticles to where they need to go while keeping healthy tissues as far away as possible. This trait is especially helpful for lowering the systemic toxins that usually comes with other drug transport methods. Adding proteins to MSNs, like antibodies, peptides, or small chemicals that bind directly to overexpressed receptors on target cells, is one of the main ways that they are targeted. Folate receptors are overexpressed in many types of cancer cells, which is why folic acid is often used to change the surface of MSNs so that drugs can be delivered more precisely. Similarly, employing antibodies or peptides unique to tumours can help to target medication delivery more precisely, therefore enhancing treatment outcomes and reducing undesired side effects. One can also modify the surface of MSNs to get passive targeting. Increased permeability and retention (EPR) impact allows nanoparticles to collect mostly in cancer tissue due of blood vessels leaking. Targeting medication distribution using MSNs also allows the medicine to be delivered gradually at the site of action.

B. Cancer therapy applications

Cancer treatment is one of the most researched uses for mesoporous silica nanoparticles (MSNs) because they can effectively hold anticancer drugs and release them in a controlled, focused way over a long period of time. Given the traditional approach, chemotherapeutic medications can find it difficult to dissolve and produce undesired side effects. MSNs provide a fresh approach to raise their therapeutic efficacy and consumption. Using MSNs to cure cancer is fantastic in that it allows one to modify their surface area to suit varied hole sizes. They may therefore carry a wide range of chemo medicines, including ones like doxorubicin (DOX), paclitaxel, and cisplatin that dislike water.

These medicines are typically contained within the mesopores of MSNs most of the time. This helps them to be released gradually over time and maintains them steady and guards against breakdown. Changing the properties of the MSNs—such as their size of pores and how they are functionalised on the outside—you may alter the rate of medication release. To make the medicine within them come out in response to the tumours surroundings, you may also employ outside elements as pH, temperature, or light. Making therapy less uncomfortable also depends much on MSNs. The drug-loaded nanoparticles may be transported straight to the cancer location by including tumour-targeting ligands—such as antibodies or peptides—on the surface of MSNs.

C. Controlled release systems

The development of controlled release systems employing mesoporous silica nanoparticles (MSNs) marks one of the most significant developments ahead in medication delivery. These methods let medications be consistently and regularly supplied. Made to release medications gradually over an extended length of time, controlled release systems This implies that pharmaceuticals don't have to be administered as regularly and there is less risk that their amounts would vary from peak to drop, which might result in either insufficient or undesired side effects. MSNs are ideal for controlled release applications as their highly organised pores are modifiable. The mesoporous form allows several drug molecules to fit within the holes, and surface characteristics of the particle and outside variables like pH, temperature, or ionic strength allow one to regulate the release. Drugs, for example, can be released as the pH shifts. This is particularly beneficial for obtaining medications to locations where the pH is altered, such as tumours or the digestive system, where it differs from in healthy tissues.

MSNs release medications using materials that change colour in response to heat or outside stimuli like light or magnetic fields as well. This increases your even more influence on the transportation procedure. Changing the surface chemistry will also affect the rate of medication release from MSNs. For instance, the surface of MSNs can be covered with polymers or other coatings to prevent medications from being released too early in physiological settings. The medications are thus only released when they get to their intended destination. MSNs are useful for making drugs for long-term diseases or conditions that need care, like cancer, diabetes, and infectious diseases, because they can control the release rates.Treatment agents can be given more efficiently and precisely by using MSNs as a base for controlled drug release.

VI. Result and Discussion

Mesoporous silica nanoparticles (MSNs) were very good at enclosing drugs and releasing them in a controlled way for a wide range of treatment agents, such as antibiotics and chemotherapeutic drugs. Because MSNs have a large surface area and pores that can be changed in size, they can

hold a lot of drugs. Adding targeted ligands to the surface made the drugs more specific and lessened their effects on other things. Changes were made to the surface chemistry, hole size, and external cues to control the release of drugs.

Table 2: Drug Encapsulation Efficiency and Release Kinetics

Drug Type	Encapsulation Efficiency (%)	Cumulative Release at 24h (%)	Cumulative Release at 48h (%)	Cumulative Release at 72h (%)
Doxorubicin	85.2	45.3	65.8	80.1
Paclitaxel	90.5	50.1	70.2	85
Cisplatin	88.3	40.8	60.5	75.4
Tetracycline	92.1	55.7	74.3	88.6

In Table 2, you can see how well four different drugs were contained in mesoporous silica nanoparticles (MSNs) and how quickly they were released. There are differences in how well the drugs are encapsulated. Tetracycline is the best at 92.1%, followed by Paclitaxel (90.5%), Cisplatin (88.3%), and Doxorubicin (85.2%). The total drug release development over 72 hours is shown in Figure 3. This shows that the release is continuous



Figure 3: Cumulative Drug Release Progression Over 72 Hours

Based on these results, MSNs are very good at encasing different kinds of drugs. Tetracycline had the best loading capacity of all the drugs that were studied. The total amount of drugs released over 24, 48, and 72 hours shows that all four drugs have continuous release over time. Figure 4 shows the drug release patterns and how well the capsules encapsulated the drug over time, showing controlled release.



Figure 4: Encapsulation Efficiency and Drug Release Profiles Over Time

Tetracycline has the best release rates at all time points: 55.7% after 24 hours, 74.3% after 48 hours, and 88.6% after 72 hours. And Doxorubicin has the least amount of total release at all times: 45.3% at 24 hours, 65.8% at 48 hours, and 80.1% at 72 hours. This steady release characteristic helps keep effective drug amounts high for longer periods of time, which may improve treatment results while reducing the need to take the drug more often

Table 3: Targeting Efficiency and Cellular Uptake

Drug Type	Targeting Efficiency (%)	Cellular Uptake at 6h (%)	Cellular Uptake at 12h (%)	Cellular Uptake at 24h (%)
Doxorubicin	78.4	35.6	50.3	63.4
Paclitaxel	82.1	38.2	54.5	68.7
Cisplatin	75.3	33.8	48.2	58.9
Tetracycline	85	40.4	58.9	72.1

In Table 3, you can see how well four drugs encased in mesoporous silica nanoparticles (MSNs) target cells and how well they are taken up by cells. The aiming effectiveness for each drug varies, ranging from 75.3% for Cisplatin to 85% for Tetracycline. This shows that MSNs are not always successful at getting drugs to the right place. Tetracycline has the best targeting efficiency, which shows that the drug-loaded MSNs have a strong contact with the target site, which could improve the accuracy of therapy. Figure 5 shows how drugs are taken in by cells over time, showing how they slowly get inside cells and build up.



Figure 5: Cellular Uptake of Drugs Over Time

The statistics on cellular uptake shows that all drugs are being taken in more and more over time. It's not very high at 6 hours; Doxorubicin only gets taken up by 35.6% of cells and Tetracycline by 40.4%. By 12 hours, all drugs are being taken in more, but Paclitaxel and Tetracycline are being taken in the most, at 54.5% and 58.9%, respectively. Figure 6 shows the total development of cellular uptake over time, which shows that cells are taking in more and more drugs



Figure 6: Cumulative Cellular Uptake Progression over Time

At 24 hours, cellular uptake is still going up. Again, Tetracycline has the best uptake at 72.1%, followed by Paclitaxel at 68.7%. This steady rise in cellular uptake shows how well MSNs work at keeping the drugs inside them for a long time. Drugs like Tetracycline and Paclitaxel were taken up and targeted more efficiently by MSNs.

CONCLUSION

Drug delivery and encapsulation of mesoporous silica nanoparticles (MSNs) are made easy by their many beneficial structural characteristics. Among these features are large surface area, biocompatibility, and changeable size holes. Because they can contain a broad spectrum of pharmaceuticals, including antibiotics, biologics, and hydrophobic medicinal agents, MSNs are a versatile carrier for a great variety of therapeutic purposes. Their large surface area and connected hole networks help them to store and release several medications gradually more easily. This guarantees longer lifetime and improved performance of the medications. Particularly more efficiently when they are changed with various surface partners, MSNs may be utilised for particular drug delivery. Targeting molecules such as antibodies, peptides, or small molecules helps MSNs to deliver medications selectively to certain cells or organs, therefore lowering adverse effects and increasing the therapeutic efficacy. This is especially helpful in cancer treatment, where specific drug transport can make chemotherapy drugs much less harmful and improve the effectiveness of treatment. Using MSNs in combination medicines, where more than one drug or healing agent is packed into a single nanoparticle, could help get around drug resistance and make treatment work better overall. Because MSNs are biodegradable and biocompatible, they can also be used in hospital settings because they can be safely broken down and flushed out of the body after their medicinal purpose is complete.

REFERENCE

1. Isa, E.D.M.; Ahmad, H.; Rahman, M.B.A.; Gill, M.R. Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment. Pharmaceutics 2021, 13, 152.
2. Jinhyun, H.L.; Yeo, Y. Controlled Drug Release from Pharmaceutical Nanocarriers. Chem. Eng. Sci. 2015, 24, 75–84.
3. Arriagada, F.; Nonell, S.; Morales, J. Silica-Based Nanosystems for Therapeutic Applications in the Skin. Nanomedicine 2019, 14, 2243–2267.
4. Schmidt, L.M.; dos Santos, J.; de Oliveira, T.V.; Funk, N.L.; Petzhold, C.L.; Benvenutti, E.V.; Deon, M.; Beck, R.C.R. Drug-Loaded Mesoporous Silica on Carboxymethyl Cellulose Hydrogel: Development of Innovative 3D Printed Hydrophilic Films. Int. J. Pharm. 2022, 620, 121750.
5. de Oliveira, R.S.; Funk, N.L.; dos Santos, J.; de Oliveira, T.V.; de Oliveira, E.G.; Petzhold, C.L.; Costa, T.M.H.; Benvenutti, E.V.; Deon, M.; Beck, R.C.R. Bioadhesive 3D-Printed Skin Drug Delivery Polymeric Films: From the Drug Loading in Mesoporous Silica to the Manufacturing Process. Pharmaceutics 2022, 15, 20.
6. Esfahani, M.K.M.; Alavi, S.E.; Cabot, P.J.; Islam, N.; Izake, E.L. Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy. Pharmaceutics 2022, 14, 1579.
7. Shen, Z.; Wen, H.; Zhou, H.; Hao, L.; Chen, H.; Zhou, X. Coordination Bonding-Based Polydopamine-Modified Mesoporous Silica for Sustained Avermectin Release. Mater. Sci. Eng. C 2019, 105, 110073.
8. Baron, L.F.; Noé, F.; Maciag, S.S.; Aparecida, F.; Bellaver, V.; Mércia, A.; Ibeli, G.; Antônio, M.; Mores, Z.; De Almeida, G.F.; et al. Toltrazuril-Loaded Polymeric

Nanocapsules as a Promising Approach for the Preventive Control of Coccidiosis in Poultry. Pharmaceutics 2022, 14, 392.
9. Kim, D.H.; Kim, Y.W.; Tin, Y.Y.; Soe, M.T.P.; Ko, B.H.; Park, S.J.; Lee, J.W. Recent Technologies for Amorphization of Poorly Water-Soluble Drugs. Pharmaceutics 2021, 13, 1318.
10. Murugan, B.; Sagadevan, S.; Lett, A.; Fatimah, I.; Fatema, K.N.; Oh, W.-C.; Mohammad, F.; Johan, M.R. Role of mesoporous silica nanoparticles for the drug delivery applications. Mater. Res. Express 2020, 7, 102002.
11. Karges, J.; Díaz-García, D.; Prashar, S.; Gómez-Ruiz, S.; Gasser, G. Ru (II) Polypyridine Complex-Functionalized Mesoporous Silica Nanoparticles as Photosensitizers for Cancer Targeted Photodynamic Therapy. ACS Appl. Bio Mater. 2021, 4, 4394–4405.
12. Porrang, S.; Rahemi, N.; Davaran, S.; Mahdavi, M.; Hassanzadeh, B. Preparation and in-vitro evaluation of mesoporous biogenic silica nanoparticles obtained from rice and wheat husk as a biocompatible carrier for anti-cancer drug delivery. Eur. J. Pharm. Sci. 2021, 163, 105866.
13. Saputra, O.A.; Wibowo, F.R.; Lestari, W.W. High storage capacity of curcumin loaded onto hollow mesoporous silica nanoparticles prepared via improved hard-templating method optimized by Taguchi DoE. Eng. Sci. Technol. Int. J. 2022, 33, 101070.
14. Nguyen, N.H.; Truong-Thi, N.-H.; Nguyen, D.T.D.; Ching, Y.C.; Huynh, N.T.; Nguyen, D.H. Non-ionic surfactants As co-templates to control the mesopore diameter of hollow mesoporous silica nanoparticles for drug delivery applications. Colloids Surf. A Physicochem. Eng. Asp. 2022, 655, 130218.
15. Rhew, K.; Chae, Y.-J.; Chang, J.-E. Progress and recent trends in photodynamic therapy with nanoparticles. J. Pharm. Investig. 2022, 52, 587–599.
16. Ravindranath, N.; Samanta, A.; Samanta, S. (2025). Dose-dependent toxicity and field efficacy of PEG-emulsified botanical formulations against chickpea pod borer (Helicoverpa armigera). Journal of Entomological Research, 49(3), 632–637. https://doi.org/10.5958/0974-4576.2025.00110.3